INS and diabetes mellitus: On the other hand, the presence of performance metrics that evaluate providers on management of their patients with diabetes (e.g., glycemic control as measured by HbA1c) could disincentivize providers from reducing or discontinuing insulin or sulfonylureas, despite guidance for relaxed treatment targets [48–50].